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Abstract : Serum levels of tumor markers, such as carcinoembryonic antigen （CEA） 
and carbohydrate antigen 19-9 （CA19-9）, are often measured to detect potential 
malignancy.  When these levels are high, the presence or absence of malignancy is 
conrmed via a more detailed examination using gastrointestinal （GI） endoscopy 
and computed tomography.  The rate of conrmation of malignancy upon such a 
follow-up is unknown.  This study aimed to investigate the malignancy detection 
rate via GI endoscopy for patients with high levels of serum CEA and CA19-9.  
All patients who underwent such GI endoscopy between January 2018 and Febru-
ary 2019 at Showa University Hospital were included in this study.  The patients 
were divided into a follow-up group and a screening group, depending on the 
purpose of measuring their serum CEA/CA19-9 levels.  There were 156 patients 
who underwent GI endoscopy because of high CEA/CA19-9 levels within the study 
period.  Advanced malignant lesions were detected in 10 patients （6.4％）, including 
seven cases of colorectal cancer and three cases of upper GI malignancies.  In the 
screening group, six cases （5.7％） of GI malignancies were detected, none of which 
were found in asymptomatic patients without anemia.  In the follow-up group, four 
cases （7.8％） of GI malignancies were detected; three patients were asymptomatic, 
and one patient had anemia.  Our ndings suggest that high serum CEA/CA19-9 
levels in asymptomatic patients without anemia and without a history of malig-
nancy do not indicate the presence of malignancy.  However, high serum CEA/
CA19-9 levels may indicate the potential presence of GI malignancies for patients 
with a history of malignant tumors, even if they are asymptomatic and do not 
have anemia.
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Introduction
　Gastrointestinal （GI） cancer is one of the leading causes of morbidity and mortality from 
malignant disease in Western and Asian countries.  Globally, colorectal cancer is the fourth and 
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gastric cancer the sixth most common malignancy1）.  In Japan, population-based cancer screening 
is conducted for gastric, colorectal, lung, breast, and uterine cancer.  Because of the high inci-
dence of gastric cancer, population-based screening is recommended for individuals older than 50 
years, either annually, by performing conventional double-contrast barium radiography, or bienni-
ally, by performing upper GI endoscopy2，3）.  In Japan, a fecal immunochemical test is performed 
for population-based colorectal cancer screening.
　The most effective modality to detect both gastric and colorectal cancer is an endoscopic 
examination, and the gold standard for cancer diagnosis is a pathological examination, usually by 
endoscopic biopsy.  Therefore, upper GI endoscopy and colonoscopy are recommended if abnor-
malities are found during primary screening.  Private medical facilities in Japan offer various 
kinds of individual screening at the patient’s own cost.  These tests often entail measuring serum 
levels of tumor markers, such as carcinoembryonic antigen （CEA） and carbohydrate antigen 19-9 
（CA19-9）, as only a blood sample is required4-8）.  CEA levels are useful for surgical treatment 
planning, posttreatment follow-up, and determining the prognosis of patients diagnosed with 
colorectal cancer9）.  Additionally, a meta-analysis reported by Deng et al.  suggested that preop-
erative elevation of CEA levels is an independent indicator of adverse prognosis10）.  However, 
low rates of sensitivity, particularly in the early stages of the disease, prevent the use of any of 
these serologic markers to diagnose colorectal and gastric cancer9，11-13）.  Moreover, elevated levels 
of CEA may also be caused by benign diseases, such as gastritis, peptic gastroduodenal ulcer-
ation, diverticulitis, liver disease, chronic obstructive pulmonary disease, diabetes, and any acute 
or chronic inammation14）.  From the viewpoint of lifestyle factors, CEA levels are signicantly 
higher in smokers than in non-smokers15，16）.
　When tumor marker levels are high, a more detailed examination is performed with the help 
of GI endoscopy or computed tomography to conrm the presence or absence of malignancy. 
However, the rate of conrmation of malignancy upon such a follow-up is unknown.  In this 
study, we investigated the rate of malignancy, as determined by endoscopic examination, for 
patients with high tumor marker levels.
Patients and methods
　The present study was conducted according to the guidelines of the Declaration of Helsinki 
and was approved by the Ethics Committee on Human Studies of Showa University, Tokyo, 
Japan.  This was a retrospective, single-center study of consecutive patients who underwent GI 
endoscopy between January 2018 and February 2019 at Showa University Hospital.
　Data （age, sex, symptoms at rst hospital visit, family history of malignant disease, endoscopic 
ndings, pathological ndings of endoscopic biopsy, blood count, and serum CEA and CA19-
9 levels） of patients who underwent endoscopy because of high serum CEA and CA19-9 levels 
were obtained from their electronic medical records.  The patients were classied into two groups 
according to the purpose of measuring their serum CEA/CA19-9 levels : a follow-up group, with 
previously identied malignant tumors, or a screening group, for whom regular cancer screening 
was undertaken.  The cut-off values of serum CEA and CA19-9 levels in this study were set at 
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5 and 34 ng/ml, respectively.  Patients with a blood hemoglobin concentration ＜ 14 g/dl for males 
and ＜ 12 g/dl for females were declared to have anemia, according to the standard reference 
ranges used at our hospital.
Statistical analysis
　Data are presented as frequencies and percentages.  The imputed data were statistically 
analyzed using JMP Pro 14 for Windows （SAS Institute Inc., Cary, NC, USA）.  A descriptive 
analysis was performed, and differences between the groups were tested using the Chi-square test 
and the Mann–Whitney U test.  A p-value ≤ 0.05 was considered statistically signicant.
Results
Patient characteristics
　There were 156 patients who underwent GI endoscopy （upper GI endoscopy and/or colo-
noscopy） because of high CEA/CA19-9 levels within the study period.  Table 1 describes the 
patients’ baseline characteristics.  There were 121 patients with elevated CEA levels （77.6％） and 
50 patients with elevated CA19-9 levels （32.1％）.  The average hemoglobin concentration was 
Table 1.  Patient characteristics
N＝ 156
Age year, mean±S.D （range） 65.6±13.6 （30-90）
Sex
Male 　　　　 （％）  76 （48.7）
Felmale　　　 （％）  80 （51.3）
Symptom
Syptomatic 　　（％）  46 （29.5）
Asymptomatic　（％） 110 （70.5）
History of MD
Present　　　　（％）  51 （32.7）
Absent　　　　（％） 105 （67.3）
Anemia
Present　　 　 （％）  63 （40.4）
Absent 　　 　 （％）  92 （59.0）
Not performed （％）  1 （0.6）
CEA
  ≧ 5 ng/ml 121 （77.6）
＜ 5 ng/ml  28 （17.9）
n,m  7 （4.5）
CA19-9
 ≧ 37 ng/ml  50 （32.0）
＜ 37 ng/ml  70 （44.9）
n,m  36 （23.1）
UGE
Performed  156 （100.0）
Not performed  0 （0）
CS
Performed 140 （89.7）
Not performed  16 （10.3）
S.D; standard deviation, MD; malignant disease, n,m; not measured, 
UGE; upper GI endoscopy, CS; colonoscopy
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13.6 and 12.5 g/dl for male and female patients, respectively, and 40 male （52.6％） and 23 female 
（28.8％） patients were anemic.  There were 51 patients （32.7％） in the follow-up group and 
105 （67.3％） in the screening group.  In total, 139 patients （89.1％） underwent a colonoscopy 
at Showa University Hospital, one patient （0.64％） underwent colonoscopy at another medical 
facility, and 16 patients （10.3％） did not undergo colonoscopy, either due to age or because no 
request was made.
Detected malignant disease
　Malignant lesions were detected in 10 patients （6.4％）.  Three of them （1.9％） were diagnosed 
with malignancy during upper GI endoscopy, and seven （4.5％） were diagnosed with colorectal 
cancer during colonoscopy.  The details of these malignant lesions are presented in Table 2.
　Table 3 summarizes the statistical signicance of the cancer detection rate in terms of the 
Table 2.  Cases with newly detected gastrointestinal malignancies
Case Sex Age Tumor maker Diagnosis Symptom History of MD Anemia CEA CA19-9 Pathology
 1 Male 71 CEA Advanced colon cancer ＋ gastric cancer -  9.1 14 adenocarcinoma
 2 Male 68 CEA/CA19-9 Advanced colon cancer ＋ - -  5.8 491.1 adenocarcinoma（tub2～ por）
 3 Male 74 CEA Advanced colon cancer ＋ - - 40.8 156.6 adenocarcinoma（tub1）
 4 Male 68 CEA Early colon cancer - lung cancer -  7.1  4.4 adenocarcinoma in adenoma
 5 Male 85 CEA/CA19-9 gastric malignant lymphoma ＋ - -  9.5 3931.8 atypical lymphoid cells
 6 Male 69 CEA Advanced EGJ cancer - esophageal cancer - 33.2   41.8 EGJ carcinoma.sig＋ tub1
 7 Male 77 CEA/CA19-9 Advanced duodenal cancer - bile duct cancer ＋ 11.2 1729.7 adenocarcinoma
 8 Female 76 CEA Advanced colon cancer - - ＋ 25.7 n,m adenocarcinoma（tub2）
 9 Male 74 CEA Advanced colon cancer ＋ - ＋  5.3 34 adenocarcinoma（tub2）
10 Male 46 CEA Early colon cancer ＋ - ＋  6.8 　18.2
Early colonic adenocarcinoma
（tub1） in adenoma
MD; malignant disease, EGJ; esophagogastric junction
Table 3.  Signicance of cancer detection rate by patient background
GI malignancy＋ GI malignancy- p value
N＝ 10 N＝ 146
Age year, mean±S.D 70.8±10.1 65.3±13.7   0.22
Sex
M　　　　　　（％）  9 （11.8）  67 （88.2）
＜ 0.01＊
F　　　　　　（％） 1 （1.3）  79 （98.8）
Group
Follow-up　　 （％） 4 （7.8）  47 （92.2）
  0.61Screening　　 （％） 6 （5.7）  99 （94.3）
Symptom
Syptomatic　　（％）  6 （13.0）  40 （87.0）
  0.03＊Asymptomatic （％） 4 （3.6） 106 （96.4）
Anemia
Present　　　 （％）  7 （11.1）  56 （88.9）
  0.05Absent　　　 （％） 3 （3.3）  89 （96.7）
S.D; standard deviation, ＊; signicantly different, M/F; male/female
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patient’s background.  There were statistically significant differences in cancer detection rates 
between male and female patients （p＜ 0.01） as well as between symptomatic and asymptomatic 
patients （p＝ 0.03）.  There was no statistically signicant difference in the detection rate of GI 
malignant tumors between patients with and without anemia （p＞ 0.05）.
　As summarized in Table 4, there was no correlation between serum CEA levels and the presence 
of GI malignancy （p＝ 0.61）.  Similar results were observed for serum CA19-9 levels （p＝ 0.16）.
Screening group
　In the screening group, six cases （5.7％） of GI malignancies were detected, of which ve were 
colorectal cancer （four advanced cancer and one mucosal cancer）, and one was gastric malignant 
lymphoma （see Tables 2 and 3）.  Of these six patients, ve were symptomatic at the rst visit 
to our hospital, and all patients were found to be anemic via blood tests.  In the screening 
group, there was a statistically significant difference in the detection rate of GI malignancies 
in patients with or without symptoms and anemia （p＝ 0.04 and p＜ 0.01, respectively）.  Fur-
thermore, no GI malignancies were detected in asymptomatic patients without anemia in the 
screening group （Fig. 1）.  Only 27 patients （25.7％） underwent cancer screening before undergo-
ing endoscopy, whereas 78 patients （74.3％） had not previously undergone any cancer screening. 
Table 4.  Relationship between CEA/CA19-9 and the presence of gastrointestinal malignancy
unit Total GI malignancy＋ GI malignancy- p value
CEA level　 （n＝ 121） ng/mL, median   7.3   7.2  7.3 0.61
CA19-9 level （n＝   50） ng/mL, median 101.0 156.6 34.0 0.16
Fig. 1.   Flow chart of the screening group based on their symptoms and the 
presence of anemia. There was no patient with GI malignancy without 
symptoms and anemia.
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Moreover, of the six patients with malignant tumors in this group, only one had previously 
undergone cancer screening （colorectal）, and the remaining ve with GI malignancy had never 
undergone cancer screening.
Follow-up group
　Four cases （7.8％） of GI malignancies were detected in the follow-up group （see Tables 2 and 3）. 
Of them, one had esophageal gastric junction cancer, one had duodenal cancer, and two had 
colon cancer （one early and one advanced）.  In the follow-up group, six patients （11.8％） were 
symptomatic when the tumor markers were measured, and only one patient was found to have 
GI malignant disease, specically advanced colon cancer.  There were 25 （49.0％） patients in 
the follow-up group who were anemic, and of them, only one was found to have GI malignant 
disease （advanced duodenal cancer） （Fig. 2）.  In the follow-up group, 24 patients （47.1％） had 
undergone upper GI endoscopy, and 27 patients （52.9％） had undergone colonoscopy.  Of the 
four patients with newly detected GI malignancy in this group, two patients had not undergone 
GI endoscopy in the previous three years.
Discussion
　In this study, we investigated the incidence of GI malignant disease and its characteristics in 
patients who had undergone endoscopy due to high serum CEA and CA19-9 levels.  Conven-
tionally, tumor markers for GI cancer are used as ancillary indicators of therapeutic efcacy and 
as signs of recurrence of malignant tumors but are less useful as detection tools9-13）.  However, 
tumor markers are sometimes used as screening tools for cancer detection because they can be 
measured with simple blood tests.  If the tumor marker level is high, further examination is 
required to conrm the presence or absence of cancer.  In particular, serum CEA and CA19-9 
Fig. 2.   Flow chart of the follow-up group based on their symptoms and the 
presence of anemia.
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levels are sometimes high in patients with GI cancer.  For such patients, it is necessary to per-
form highly invasive examinations, such as upper GI endoscopy and colonoscopy.  Furthermore, 
for patients who have had malignant tumors in other organs, the effectiveness of GI endoscopy 
when high serum CEA and CA19-9 levels are detected during a follow-up hospital visit has not 
been claried.
　In the present study, most of the patients had high serum CEA levels.  Because of the small 
number of patients that were negative for CEA, it was difcult to compare these results with 
those of previous studies regarding the efcacy of using serum CEA levels to detect GI malig-
nancies.  However, as shown in Table 4, CEA levels were not signicantly correlated with the 
presence of GI malignancies.
　In this study, patients were divided into a follow-up group and a screening group, due to dif-
ferences in the reason for measuring CEA and CA19-9 levels and in potential cancer risks.  The 
GI malignancy detection rate was not signicantly different between the two groups, suggesting 
that the serum CEA and CA19-9 levels were not correlated with GI malignancy detection via 
endoscopy for patients as a whole.
　Serum CEA levels are known to be affected by other factors such as aging and smoking14-16）.  It 
is possible that patients in the current study were a mixture of smokers and non-smokers.  Patients’ 
smoking habits were not available for this study.  However, it is difficult to determine whether 
elevated CEA levels are due to smoking or malignancy before scanning.  Therefore, the presence of 
a smoking habit seems to be difcult to become the reason for not doing the endoscope.
　This study showed that these patients’ symptoms were signicantly associated with the detec-
tion of GI malignant disease （see Table 3）, anemia tended to be associated with the detection 
of GI malignancies, although this was not statistically signicant.  These tendencies were espe-
cially signicant for patients with high CEA and CA19-9 levels without a history of malignant 
diseases （screening group）.  There was a statistically signicant difference in the detection rate 
of GI malignancies with or without symptoms and anemia in the screening group.  Of the six 
patients with newly detected GI malignancies in the screening group, only one was asymptomatic, 
and three patients had anemia.  The asymptomatic patient who had advanced colorectal cancer 
had not received population-based cancer screening, and this case could have been detected with-
out measuring tumor marker levels if a fecal immunochemical test would have been performed.
　For asymptomatic patients in the study, GI malignancies were more frequently detected in the 
follow-up group （6.7％） than in the screening group （1.5％）.  In the follow-up group, 49.0％ and 
51.0％ of patients had not previously undergone upper GI endoscopies and colonoscopies, respec-
tively.  This suggested that patients with a history of malignant tumors may need to be screened 
for GI cancer regularly, even if they are asymptomatic.
　This study suggests that high serum CEA/CA19-9 levels may not be an accurate indication of 
GI malignancy for asymptomatic patients without anemia who have never been diagnosed with 
cancer.  Thus, GI endoscopy for these patients might be unnecessary.  By avoiding unnecessary 
examinations, medical resources and medical costs can be reduced, and the risk of complications 
associated with endoscopy may be avoided.  Endoscopy is often considered a major risk for the 
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elderly ; therefore, it is recommended that such invasive examinations only be performed after 
conrming the presence of symptoms and anemia.
　Currently, the number of people undergoing population-based cancer screening in Japan is 
low17）.  This is reected in the current study, where a low number of screening group patients 
had previously undergone population-based cancer screening （25.7％, data not shown）.  This 
may be due to the low tolerability of conventional double-contrast barium radiography, upper 
GI endoscopy, and the fecal immunochemical test.  In recent years, new tumor markers, such 
as CA11-1918，19）, have been identified, and blood-based gene biomarker panels have been 
developed20）.  It is essential to develop methods to improve the patient screening rate, thereby 
increasing the cancer detection rate.  However, of the screening tools currently in use, the sim-
pler methods are less effective than the more invasive ones.  Therefore, new screening methods 
need to be developed, and the signicance of tumor marker tests should be explained to the 
patient to improve the patient screening rate.
　Second, among patients with high serum CEA/CA19-9 levels, only those who had undergone 
GI endoscopy were investigated.  Therefore, the detection rate of malignant GI tumors for 
patients with high tumor marker levels in this study cannot be compared with the rates found in 
previous studies.
　In conclusion, GI endoscopic examination is not recommended for patients with high serum 
CEA/CA19-9 levels who are asymptomatic, have no anemia, and have no history of malignancy. 
Furthermore, for patients with a history of malignant tumors and high serum CEA/CA19-9 levels, 
GI malignancies may be present, even if the patients are asymptomatic and without anemia.
　There were some limitations to this study.  First, this was a single-center, retrospective study 
with a limited population size.  Second, among patients with high serum CEA/CA19-9 levels, 
only those who have undergone gastrointestinal endoscopy were investigated.  Therefore, the 
detection rate of malignant GI tumors for patients with high tumor marker levels in this study 
cannot be compared with the rates found in previous studies.
　In conclusion, GI endoscopic examination is not recommended for patients with high serum 
CEA/CA19-9 levels who are asymptomatic, have no anemia, and have no history of malignancy. 
Furthermore, for patients with a history of malignant tumors and high serum CEA/CA19-9 levels, 
GI malignancies may be present even if the patients are asymptomatic and without anemia.
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